IMbrave 151 is a randomized, double-blind, placebo-controlled, multicenter, international phase II study on atezolizumab (PD-L1 inhibitor) in combination with chemotherapy (Gem+Cis) and bevacizumab (anti-VEGF monoclonal antibody) as first-line therapy for advanced CCA. Here, VEGFA is linked to cholangiocarcinoma.